VERTEX PHARMACEUTICALS INC / MA Write off of Deferred Debt Issuance Cost
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Write off of Deferred Debt Issuance Cost of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2016-02-16
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for the quarter ending 2014-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for the quarter ending 2014-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for the quarter ending 2013-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for the quarter ending 2013-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for fiscal 2015 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for fiscal 2013 was $4.23M.
- VERTEX PHARMACEUTICALS INC / MA write off of deferred debt issuance cost for fiscal 2012 was $0.00.
| Period end | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month | Write off of Deferred Debt Issuance Cost 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-16 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 derived: sum of 2 quarters · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $0.00 10-Q · filed 2014-07-31 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 derived: sum of 2 quarters · filed 2016-02-16 | $4.23M 10-K · filed 2016-02-16 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $4.23M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $4.23M 10-Q · filed 2014-07-31 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-02-11 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $0.00 derived: sum of 2 quarters · filed 2013-03-01 | $0.00 derived: sum of 3 quarters · filed 2013-03-01 | $624.00K 10-K · filed 2013-03-01 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $0.00 derived: sum of 2 quarters · filed 2011-11-03 | $624.00K 10-Q · filed 2011-11-03 | $3.05M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-09 | $624.00K 10-Q · filed 2011-08-09 | $3.05M derived: sum of 3 quarters · filed 2012-02-22 | $3.05M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $624.00K 10-Q · filed 2011-05-06 | $3.05M derived: sum of 2 quarters · filed 2012-02-22 | $3.05M derived: sum of 3 quarters · filed 2012-02-22 | |
| 2009-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $2.42M derived: sum of 2 quarters · filed 2012-02-22 | $5.90M 10-K · filed 2012-02-22 | |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $3.48M 10-Q · filed 2010-10-28 | ||
| 2009-06-30 | $3.48M 10-Q · filed 2010-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |